Amgen (AMGN) will report first-quarter 2024 results on May 2, before market open. In the last reported quarter, the company beat earnings expectations by 1.07%.Factors to ConsiderAmgen’s product sales are expected to be the lowest in the first quarter per historical trends due to the impact of benefit plan changes, insurance re-verification and increased co-pay expenses as U.S. patients work through deductibles. First-quarter 2024 total revenues are expected to grow roughly 20% year over year. The Zacks Con ...

Analysts on Wall Street project that Amgen (AMGN) will announce quarterly earnings of $3.76 per share in its forthcoming report, representing a decline of 5.5% year over year. Revenues are projected to reach $7.38 billion, increasing 20.9% from the same quarter last year.The consensus EPS estimate for the quarter has undergone a downward revision of 0.9% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates durin ...

THOUSAND OAKS, Calif., April 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that ca ...

Goldman Sachs Has 6 Dividend Blue Chips on Its Conviction List of Top Stocks Chris Hondros / Getty Images The artificial intelligence rally over the last year and a half, led by the so-called Magnificent 7, has been remarkable if you owned those stocks. However, most of the S&P 500 is treading water and will not likely catch up to the hype-driven AI stocks soon.One thing remains certain: with storm clouds gathering on the horizon and the risk of an escalating conflict in the Middle East, many Wall Street ...

Dividend investing can be a profitable strategy for traders, providing an extra source of income alongside potential stock gains. Amgen (NASDAQ: AMGN) has demonstrated strong performance, surpassing the average return of the S&P 500.Since initiating dividend payouts in 2011, AMGN shares have outperformed the S&P 500, with a return of 382.28% compared to the index’s 292.76%.Comparison of returns between AMGN stock and S&P 500. Source: Barchart Earnings ratio and dividend yield make a compelling case for AMGN ...

Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.The overall market shows clear indications that it's priced at relatively rich levels right now. But smart investors willing to do a little digging will find that there are always at least a few undervalued stocks worth consideration.The real difficulty though is finding undervalued names you want to buy and hold forever. These companies must be in true "forever" businesses. And, these companies must also be ...

Planning Underway for Phase 3 Development of Tezepelumab in COPD  THOUSAND OAKS, Calif., April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT. We are encouraged by the resul ...

Due to its obvious nature, one of the most commonly repeated pieces of advice regarding stock investment is to buy undervalued stocks when they trade low and sell overvalued stocks when they trade high. Achieving this outcome consistently would be ideal. However, the challenge lies not only in identifying overvalued and undervalued stocks trading at appreciated or depressed prices but also in those with promising potential.There may be several reasons why undervalued stocks do not reflect their intrinsic va ...

Vertigo3d Anybody who's invested in the pharmaceutical space knows that industry giants like Pfizer (PFE) and Gilead Sciences (GILD) are subject to boom and bust cycles as it relates to patent cliffs and new drug development. That's why capital allocation is so important to sustaining shareholder returns, and those who can do it well tend to outperform peers and even the market itself. This brings me to Amgen (NASDAQ:AMGN), which has done well for shareholders over its history. I last covered the stock back ...

JHVEPhoto "Science Lessons" is a famous book by Gordon Binder, the now 89 year-old who led Amgen (NASDAQ:AMGN) as CEO from 1988-2000 and CFO from 1982-1988. It discusses Amgen's growth as a biopharmaceutical company, along with the company's core focuses on discovery and science in what is an incredibly tough industry. As we'll see throughout this article, despite Amgen's recent stock price stagnation, the company has one of the best portfolios in the industry, making it a valuable investment. Amgen Horizon ...